格索雷塞片(安方宁®)
Search documents
益方生物: 益方生物2024年年度股东大会会议资料
Zheng Quan Zhi Xing· 2025-06-12 11:19
Core Viewpoint - The company is preparing for its 2024 annual general meeting, focusing on governance improvements and financial reporting, while addressing its operational challenges and future strategies. Group 1: Governance and Meeting Procedures - The company has established rules for the shareholder meeting to ensure order and efficiency, including a requirement for timely attendance and registration [1][2] - The meeting will include a combination of on-site and online voting, with specific timeframes for participation [2][4] - The company will appoint representatives for counting and monitoring votes during the meeting [4][5] Group 2: Financial Performance and Reports - The company reported a net loss of 240.20 million yuan for 2024, a 15.41% reduction compared to the previous year [10][20] - Total revenue for 2024 was 168.79 million yuan, down 9.02% from 185.53 million yuan in 2023 [20][21] - Research and development expenses were maintained at a high level, totaling 384.35 million yuan, reflecting the company's commitment to innovation [10][21] Group 3: Future Plans and Proposals - The company will not distribute dividends for 2024 due to its financial situation, with a focus on maintaining operational stability [6][7] - Proposals for the 2025 financial budget and director remuneration have been prepared for shareholder approval [8][9] - The company plans to revise its governance structure by abolishing the supervisory board and transferring its responsibilities to the audit committee [9][10]